Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...

On Monday, Agios Pharmaceuticals Inc (AGIO) stock saw a decline, ending the day at $44.43 which represents a decrease of $-1.18 or -2.59% from the prior close of $45.61. The stock opened at $45.61 and ...

Leerink Partners downgraded Agios Pharmaceuticals (NASDAQ:AGIO) to Market Perform from Outperform on Friday, citing headwinds from Pfizer's (NYSE:PFE) recent decision to withdraw Oxbryta ...

Investors in Agios Pharmaceuticals, Inc. AGIO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 20, 2024 $17.50 Put had some of the ...

Investors in Agios Pharmaceuticals, Inc. AGIO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 20, 2024 $17.50 Put had some of the highest ...

Meridian Growth Fund highlighted stocks like Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), in the second quarter 2024 investor letter. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cantor Fitzgerald has recently initiated Agios Pharmaceuticals Inc (AGIO) stock to Overweight rating, as announced on February 8, 2024, according to Finviz. Earlier, on February 3, 2023, Piper Sandler ...

Agios Pharmaceuticals Inc’s current stock price and volume Why Agios Pharmaceuticals Inc’s stock price changed recently Upgrades and downgrades for AGIO from analysts AGIO’s stock price momentum as ...